The results of computed tomography (CT) For programs that satisfy these criteria, we would also suggest that there is no reason to delay screening, i.e. early diagnosis, for lung cancer.
test CT initiates a process that leads to early diagnosis. Such diagnostic activity, as it is pursued in an individual, is squarely in the domain of clinicians. In this context, we suggest that it is the responsibility of the individual clinician to decide, from the evidence at hand, whether or not to recommend screening to individuals at risk for lung cancer. The clinician should not be deterred by those who remain pessimistic concerning CT screening, or by those health policy authorities who presume to be qualified to discourage high-risk members of the population from seeking early diagnosis and potentially curative treatment of lung cancer. In a matter as important as this, clinicians should not defer to non-clinical authorities.
By definition, candidates for screening must be asymptomatic and without clinical signs to suggest lung cancer. Members of the high-risk population are identified at present according to age, exposure to cigarette smoke (current, former, or passive smoker), occupational hazards, co-existing lung disease, and family history of lung cancer.
Research efforts to refine the risk profile so that it reliably identifies an individual's unique profile are underway and will inform the screening tests of the future, which will be discussed. In the meantime, lowradiation-dose chest CT has been shown to be the most sensitive test available. Obtaining the CT is not what we consider to be screening. The CT initiates the 'regimen of screening': a management algorithm initially derived empirically and regularly revised from the data of ongoing research. When judiciously followed, this regimen leads to early diagnoses and minimizes unnecessary tests and invasive interventions, namely biopsies and surgeries. 2 We believe that it is not appropriate to initiate a screening program without coupling the CT to a regimen of screening of the I-ELCAP type. Also essential is a team of interested specialists to collaborate and monitor compliance with the management algorithm and the quality of its diagnostic components. Computed Tomography Scanning for Lung Cancer 2007
lung cancer for the foreseeable future in the US. Our main concern, which was expressed to the trial's planners and is unchanged now, is that the trial has the capacity to produce equivocal or falsely negative results in the same way that predecessors of the RCT genre performed in the evaluation of mammography. 4 In our view, to wait for NLST results before starting to screen is to fail to cure many curable cases of lung cancer.
Two lines of criticism of I-ELCAP type screening have been monotonously repeated and are grossly misleading. First, the frequency of 'falsepositives'-defined as lung nodules detected by CT that require additional evaluation but are not cancers-has been cited by some to be as high as 40%. 5 As a consequence, unnecessary tests and biopsies are carried out with their attendant costs and morbidity. However, the fact is are less frequent than at baseline. Second, seemingly by rote, and with intention to suggest that CT screening for lung cancer is sure to fail, critics recite the familiar litany of biases: lead time, length time, and overdiagnosis. To these we have answered that the very objectives of screening for lung cancer, or any cancer, are to provide lead time and to diagnose latent, curable cancer. 6 There is no bias introduced, unless one uses short-term survival rates (five years) to compare screening with nonscreening results to indicate the effectiveness and the success of screening. I-ELCAP does not do that.
We report long-term, 10-year rates, which in lung cancer equate with CT-guided fine-or core-needle biopsy is the preferred technique.
Realtime on-site cytology interpretation provides immediate information about the adequacy of the specimen or need for additional samples.
When needle biopsy is not possible, a bronchoscopic or image-assisted thoracosopy procedure is carried out. Limited thoracotomy for early diagnosis is rarely required. For critics 5, 8 to suggest that I-ELCAP screening may "do more harm than good" (the harm consisting of morbidity or mortality from unnecessary biopsies and surgeries) is to be grossly uninformed of the tenets on which the I-ELCAP study design rests.
Furthermore, the critical role of the screening-coupling the CT test to explicit means of achieving early diagnosis-causes minimal adverse effects while maximizing favorable outcomes. Once the diagnosis of lung cancer is made, the diagnostic mission of screening is complete.
The screening subject, now a patient with a life-threatening disease, • definitively diagnose early lung cancer without biopsy; and
• ultimately predict its development and the opportunity for primary lung cancer prevention.
It has been said that functional genomic and proteomic research will launch the next era of cancer molecular medicine. Molecular biologic techniques have been applied to lung cancer diagnostics since the 1990s.
The linkage of the techniques of polymerase chain reaction, bioinformatics, high-throughput analysis, and molecular hybridization has led to the development of arrays of genes specific to an organ (e.g. its accelerating capacity to demonstrate function, as well as microstructure to the cellular level, is expected to compete favorably with these other products of research, at least for the next decade.
All of these lines of investigation create great expectations for the future.
However, the clinician who fantasizes that the ideal approach to lung cancer prevention will become a reality in his or her lifetime is quickly sobered when he or she reflects that, even if all cigarette smoke exposure were to stop today, there would remain a reservoir of millions of at-risk individuals, many of whom will die of the disease under the present pessimistic healthcare policies concerning screening. Right now, the best way to increase the curability of lung cancer is by screening, as demonstrated through evidence presented by I-ELCAP. Screening may reduce lung cancer deaths by up to 75%, saving 123,500 lives in the US each year. Clinicians will recognise that two compelling indicators-the rationale for CT screening and the evidence of its effectivenessdemonstrate that now is the time to implement CT screening for individuals at risk for lung cancer. ■
